ReviewMolecules (Basel, Switzerland)2021
Role of Gut Microbiota, Probiotics and Prebiotics in the Cardiovascular Diseases.
Review in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 135 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
135 citing papers in PubMed, 2 syntheses or guidelines pooled it, 257 citations in OpenAlex.
- Urbanization gradient, diet, and gut microbiota in Sub-Saharan Africa: a systematic review.Frontiers in microbiomes · 2023Pooled it
- Impact of Obesity-Induced Inflammation on Cardiovascular Diseases (CVD).International journal of molecular sciences · 2021Pooled it
- The Effects of a Prebiotic Formula PromotingInternational journal of medical sciences · 2026Trial
- Trial
- The Gut-Heart Axis in Cardiovascular Disease: Microbial Metabolites, Mediterranean and Traditional Turkish Dietary Patterns, and Personalized Medicine.International journal of molecular sciences · 2026Review
- Gut microbiota-atrium axis: Microbiota metabolite-mediated regulation of the NLRP3 inflammasome in atrial fibrillation-pathophysiological roles and therapeutic perspectives.Heart rhythm O2 · 2026Review
- Oral hydrogel systems in lower gastrointestinal disorders: From disease-based therapy to microbiota-guided design.Materials today. Bio · 2026Review
- Gut microbiota and immune modulation: role in neurodegenerative disorders and cancer.Molecular biology reports · 2026Review
- Probiotics: A Promising Microbial Functional Food with Diverse Health Benefits.Probiotics and antimicrobial proteins · 2026Review
- Functional and Bioactive Properties of Fermented Microalgae and Their Biomass for Health Applications.Molecules (Basel, Switzerland) · 2026Review
- Galactooligosaccharides Based on β-Galactosidase-Catalyzed Synthesis: Function, Biosynthesis and Optimization Strategy.Foods (Basel, Switzerland) · 2026Review
- Microbiome-Associated Drug Response Variability in Heart Failure Treatment.Life (Basel, Switzerland) · 2026Review
- Dietary index for gut microbiota and risk of hypertension: the mediating role of HOMA-IR in a five-year prospective cohort study in Iranian adults.Nutrition & metabolism · 2026Article
- Benefits that Death Does Not Part: the Promise of Postbiotics for Bone Health.Probiotics and antimicrobial proteins · 2026Review
- Microecological Interventions against Antibiotic-Induced Dysbiosis and Related Resistome Expansion.Journal of microbiology and biotechnology · 2026Review
- The gut as a central hub for multi-organ crosstalk in aging.Cellular and molecular life sciences : CMLS · 2026Review
- Intestinal organoid screen reveals that Bacillus velezensis PGM541 promotes epithelial proliferation via its metabolite butyric acid.Microbiome · 2026Article
- The gut-heart axis in atrial fibrillation: Pathophysiology, evidence, and therapeutic potential.Heart rhythm O2 · 2026Review
- Analysis of Microbial Interactions During the Production of Chinese Ethnic Fermented Foods.Foods (Basel, Switzerland) · 2026Review
- Dietary live microbe intake and asthma risk and mediator analysis: a cross-sectional study of NHANES 2003-2018.BMC pulmonary medicine · 2026Article
75 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, there has been a growing interest in identifying and applying new, naturally occurring molecules that promote health. Probiotics are defined as "live microorganisms which, when administered in adequate amounts, confer health benefits on the host". Quite a few fermented products serve as the source of probiotic strains, with many factors influencing the effectiveness of probiotics, including interactions of probiotic bacteria with the host's microbiome. Prebiotics contain no microorganisms, only substances which stimulate their growth. Prebiotics can be obtained from various sources, including breast milk, soybeans, and raw oats, however, the most popular prebiotics are the oligosaccharides contained in plants. Recent research increasingly claims that probiotics and prebiotics alleviate many disorders related to the immune system, cancer metastasis, type 2 diabetes, and obesity. However, little is known about the role of these supplements as important dietary components in preventing or treating cardiovascular disease. Still, some reports and clinical studies were conducted, offering new ways of treatment. Therefore, the aim of this review is to discuss the roles of gut microbiota, probiotics, and prebiotics interventions in the prevention and treatment of cardiovascular disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.